Clinical trials: Hematologic
Autoimmune Thrombocytopenia
The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
- Trial name
- NCT01667263
- Testing
- All-trans retinoic acid, Danazol
- Where
- 5 sites in China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Purpura, Thrombotic Thrombocytopenic, Von Willebrand Disease Type-2b
ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
To evaluate the overall safety and tolerability of ARC1779, a therapeutic oligonucleotide ("aptamer") in patients with three types of von Willebrand Factor related platelet disorders.
- Trial name
- NCT00632242
- Testing
- ARC1779
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Archemix Corp.
Anemia of Prematurity
Autologous Cord Blood Transfusion in Preterm Infants
The purpose of this study is to investigate the efficacy and safety of autologous cord blood transfusions in very-low-birth-weight premature infants, and to evaluate the developmental outcomes of the infants who received…
- Trial name
- NCT02101086
- Testing
- Blood transfusion
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Ankara University
Smoldering Multiple Myeloma
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
- Trial name
- KIRMONO (NCT01222286)
- Testing
- IPH2101
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Innate Pharma
Anemia, Thrombocytopenia
Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a…
- Conditions
- Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
- Trial name
- NCT05634005
- Testing
- Clinical Decision Support
- Where
- United States
- Volunteers
- 1,543 people
- Sponsor
- University of Utah
Atypical Hemolytic Uremic Syndrome (aHUS)
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.
- Trial name
- NCT01770951
- Where
- 23 sites in United States, Austria and 6 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Myeloma
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
This study will use the drug daratumumab in patients who did not achieve at least a very good partial response (VGPR) and are already planned to have an Autologous Stem Cell Transplant (ASCT).
- Trial name
- NCT04230031
- Testing
- Daratumumab
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Hematopoietic and Lymphoid Cell Neoplasm
Exercise Prehab in Older Adults With Hematologic Malignancies
This pilot trial studies a structured exercise program intervention in improving physical activity in older patients with hematologic malignancies undergoing cancer therapy.
- Trial name
- NCT02791737
- Testing
- Exercise Intervention, Laboratory Biomarker Analysis, Physical Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hemoglobinopathies
Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
Worldwide, several studies report that 4.4% to 85.4% of thalassemia patients were positive for anti hepatitis C antibodies. Recently, three different studies reported the efficacy and the safety of combination therapy with…
- Trial name
- IFNRIBAHE (NCT00887081)
- Testing
- PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliera V. Cervello
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares cytarabine versus (vs.) cytarabine and venetoclax vs. liposome-encapsulated daunorubicin-cytarabine and venetoclax vs.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy
- Trial name
- NCT05554419
- Testing
- Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine
- Volunteers
- 184 people
- Sponsor
- National Cancer Institute (NCI)
Cardiovascular Disease, Hematologic Diseases
Gulf Long-Term Follow-Up Study
Background: There has been little research on the long-term health effects from oil spills, even though at least 10 percent of all oil tanker spills between 1970 and 2009 have affected coastal populations.
- Conditions
- Cardiovascular Disease, Hematologic Diseases, Immunologic Disease, Cancer
- Trial name
- NCT01287000
- Where
- United States
- Volunteers
- 32,658 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Severe Hemophilia A
Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
This study will evaluate if Eloctate is superior to Emicizumab in reducing inhibitors in children with severe hemophilia when given before the first bleed (preemptive) and continued weekly to prevent bleeds (prophylaxis); and…
- Trial name
- INHIBIT (NCT02196207)
- Testing
- Eloctate Prophylaxis, Emicizumab Prophylaxis, Eloctate ITI plus Emicizumab
- Where
- United States
- Sponsor
- Margaret Ragni
Multiple Myeloma
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
To evaluate the efficacy and safety of investigational drug Colchicine combined with conventional lenalidomide based therapy in multiple myeloma subjects who had received first-line therapy (including Chimeric antigen receptor…
- Trial name
- NCT05802992
- Testing
- Colchicine, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Iron Deficiency Anaemia, Iron Deficiency Anemia
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
- Trial name
- NCT03238911
- Testing
- Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
- Where
- 16 sites in United States
- Volunteers
- 123 people
- Sponsor
- Pharmacosmos A/S
Leukemia
PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia
This pilot study was designed in order to evaluate the safety and efficacy of an AmBisome loading dose regimen, in a weekly administration schedule, during the aplastic phase following induction or consolidation chemotherapy for…
- Trial name
- NCT00362544
- Testing
- Ambisome
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin, nirogacestat, and pomalidomide is a safe treatment for people who have relapsed or refractory multiple myeloma.
- Trial name
- NCT05556798
- Testing
- Belantamab Mafodotin, Nirogacestat, Pomalidomide
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Normal Pregnancy
Determination of Reference Values for Diluted Russell's Viper Venom Time (dRVVT) Specific to Pregnant Women (GRAPL)
Pregnancy is associated with significant changes in several aspects of haemostasis, especially an imbalance between procoagulant and anticoagulant factors.
- Trial name
- GRAPL (NCT06133621)
- Testing
- dosage dRVVT
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation.
- Trial name
- NCT07223814
- Testing
- Bleximenib, Cytarabine, Daunorubicin or Idarubicin
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 875 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Breath-holding Spell
Breath-holding Spells and Its Management Study
The goal of this prospective population-based study is to evaluate the new disease description and management guidelines for breath-holding spells in children (Hellström Schmidt et al, Acta Paediatrica 2024) below the age of 5…
- Trial name
- BAM (NCT06628271)
- Testing
- Guidelines
- Where
- 12 sites in Sweden
- Volunteers
- 120 people
- Sponsor
- Region Skane
Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Phase I trial to study the effectiveness of PS-341 in treating patients who have refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia in blast phase, or myelodysplastic syndrome.
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00005064
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.